THURSDAY, Nov. 21, 2024 (HealthDay News) -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol ...

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

Heart failure outcomes in patients with type 2 diabetes receiving once-weekly exenatide are affected by left ventricular ejection fraction.